Career history of Ira Wallis
Former positions of Ira Wallis
| Companies | Position | Start | End |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | General Counsel | - | 03/02/2014 |
| DYNAVAX TECHNOLOGIES CORPORATION | General Counsel | 01/05/2001 | 01/01/2003 |
| CERUS CORPORATION | Director/Board Member | 01/07/1996 | 01/04/2001 |
| General Counsel | 01/07/1996 | 01/04/2001 | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | General Counsel | 01/01/1990 | 01/01/1996 |
| Sandoz Pharmaceuticals Corp. | General Counsel | 01/01/1987 | 01/01/1989 |
Training of Ira Wallis
| American International College | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Statistics
International
| United States | 8 |
Operational
| General Counsel | 5 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| CERUS CORPORATION | Health Technology |
| Private companies | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Sandoz Pharmaceuticals Corp. |
- Stock Market
- Insiders
- Ira Wallis
- Experience
